Cellosaurus logo
expasy logo

Cellosaurus Ba/F3 EGFR-V769_D770insASV [Taiho Pharmaceutical] (CVCL_E6DN)

[Text version]
Cell line name Ba/F3 EGFR-V769_D770insASV [Taiho Pharmaceutical]
Synonyms Ba/F3 EGFR-V769insASV
Accession CVCL_E6DN
Resource Identification Initiative To cite this cell line use: Ba/F3 EGFR-V769_D770insASV [Taiho Pharmaceutical] (RRID:CVCL_E6DN)
Comments Genetic integration: Method=Transfection; Gene=HGNC; HGNC:3236; EGFR (Note=With p.Val769insAlaSerVal (c.2308_2309insCCAGCGTGG)).
Genetic integration: Method=Transfection; Gene=UniProtKB; P13249; Streptomyces alboniger pac (PuroR).
Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse.
Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
Cell type: Pro-B cell; CL=CL_0000826.
Species of origin Mus musculus (Mouse) (NCBI Taxonomy: 10090)
Breed/subspecies: C3H.
Hierarchy Parent: CVCL_0161 (Ba/F3)
Category Factor-dependent cell line
Publications

PubMed=29748209; DOI=10.1158/1535-7163.MCT-17-1206
Shinichi Hasako, Miki Terasaka, Naomi Abe, Takao Uno, Hirokazu Ohsawa, Akihiro Hashimoto, Ryoto Fujita, Kenji Tanaka, Takashige Okayama, Renu Wadhwa, Kazutaka Miyadera ...Show all 14 authors... , Yoshimi Aoyagi, Kazuhiko Yonekura, Kenichi Matsuo; Show fewer authors
TAS6417, a novel EGFR inhibitor targeting exon 20 insertion mutations.
Mol. Cancer Ther. 17:1648-1658(2018)

PubMed=31467113; DOI=10.1158/1541-7786.MCR-19-0419; PMCID=PMC6872223
Hibiki Udagawa, Shinichi Hasako, Akihiro Ohashi, Rumi Fujioka, Yumi Hakozaki, Mikiko Shibuya, Naomi Abe, Toshiharu Komori, Tomonori Haruma, Miki Terasaka, Ryoto Fujita ...Show all 18 authors... , Akihiro Hashimoto, Kaoru Funabashi, Hiroyuki Yasuda, Kazutaka Miyadera, Koichi Goto, Daniel Botelho Costa, Susumu S. Kobayashi; Show fewer authors
TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase inhibitor with a broad spectrum of preclinical activity against clinically relevant EGFR mutations.
Mol. Cancer Res. 17:2233-2243(2019)

Entry history
Entry creation10-Apr-2025
Last entry update14-Aug-2025
Version number2